1. Australia Stocks

  2. •

    Health technology

  3. •

    Biotechnology
LTR Pharma Limited

LTR Pharma Limited

AASX:LTP
0.48
AUD
+0.00
(-1.03%)
-0.03EPS
52.48MMarket Cap
LTR Pharma Limited
ASX:LTP
(Australian Securities Exchange)

Recent

price

0.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
AUD
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.01
-0.01
-0.05
-0.03
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
0.01
0.05
0.02
0.17
Book Value per Share
- -
0.01
0.05
0.02
0.17
Tangible Book Value per Share
139
139
139
139
167
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
-5,123.89
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-1
-7
-6
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-3,837.01
Profit Margin (%)
- -
1
7
3
31
Working Capital
- -
- -
- -
- -
- -
LT Debt
- -
2
7
3
32
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-31.43
-133.37
-32.47
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
971.58%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
-19.57%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.05
2025
- -
- -
-0.03

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
LTR Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. The company was founded by Rodne Eric Lee in October 2020 and is headquartered in Brisbane, Australia.

Company News

Company News APIChatGPT

  • gurufocus.com

    Roxus® ED Nasal Spray Now Available in the U.S.: Peak Blood Levels in About 10 Minutes, Not an Hour

  • prnewswire.com

    Roxus® ED Nasal Spray Now Available in the U.S.: Peak Blood Levels in About 10 Minutes, Not an Hour